38,721 Shares in Danaher Corporation $DHR Bought by SFE Investment Counsel

SFE Investment Counsel bought a new stake in Danaher Corporation (NYSE:DHR) during the second quarter, Holdings Channel reports. The fund bought 38,721 shares of the conglomerate’s stock, valued at approximately $7,376,000.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Norges Bank acquired a new stake in Danaher during the fourth quarter worth about $2,177,106,000. Viking Global Investors LP lifted its stake in shares of Danaher by 543.9% in the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after purchasing an additional 2,455,994 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Danaher by 11.2% in the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after purchasing an additional 1,517,904 shares in the last quarter. Capital International Investors grew its holdings in shares of Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in Danaher by 9.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after purchasing an additional 1,334,221 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on DHR shares. Morgan Stanley cut their price target on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Wolfe Research downgraded shares of Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. TD Cowen dropped their price objective on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. HSBC cut their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Citigroup began coverage on shares of Danaher in a report on Tuesday, May 26th. They set a “buy” rating and a $230.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Danaher Stock Down 0.7%

NYSE DHR opened at $202.51 on Friday. The stock has a market cap of $142.37 billion, a PE ratio of 35.97, a P/E/G ratio of 2.52 and a beta of 0.78. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The business has a 50 day moving average price of $193.14 and a two-hundred day moving average price of $193.21. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the company earned $0.77 earnings per share. As a group, sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.